Particle.news
Download on the App Store

Psoriasis Tied to Higher 10-Year AMD Risk in Large U.S. Records Study

An observed benefit with biologic therapy is prompting plans for imaging studies alongside prospective trials.

Overview

  • The EADV 2025 presentation detailed a TriNetX retrospective analysis spanning 15 years that included 22,901 patients older than 55 with psoriasis and three propensity-matched control cohorts.
  • Over a decade of follow-up, the psoriasis group showed a 56% higher incidence of age-related macular degeneration versus major depressive disorder controls and 21% higher versus melanocytic nevi controls after excluding prior cases.
  • Risk rose for both subtypes, with exudative (wet) AMD up 40% and non-exudative (dry) AMD up 13% compared with the major depressive disorder cohort.
  • Patients receiving biologic therapies had a 27% lower incidence of new AMD diagnoses than biologic-naïve peers treated only with topical corticosteroids.
  • Researchers cited shared lipid dysregulation as a plausible link, cautioned that the observational design limits causal conclusions, and advised standard eye exams while further imaging-based work proceeds.